在患有血液性恶性瘤的患者中,COVID-19疫苗的有效性:全国性的队列研究
Quincy Hofsink1,2,3, Birgit I Lissenberg-Witte4, Sabine Haggenburg1,2,3
1Department of Hematology, Amsterdam UMC, University of Amsterdam, Amsterdam, The Netherlands.
The Journal of infectious diseases
|October 15, 2025
概括
在癌症患者中,COVID-19疫苗接种降低了严重的COVID-19风险,但血液恶性瘤患者仍然面临更高的风险. 诸如恶性瘤类型和治疗等因素会影响治疗结果.
科学领域:
- 在瘤学瘤学.
- 传染性疾病 传染性疾病
- 疫苗学 疫苗学 疫苗学
背景情况:
- 在血液恶性瘤患者中,COVID-19疫苗的有效性在很大程度上是未知的.
- 缺乏关于这些患者严重COVID-19风险因素的细粒度数据.
研究的目的:
- 在患有血液性恶性瘤的患者中确定严重COVID-19结果的决定因素.
- 评估COVID-19疫苗在这个弱势群体中的有效性.
主要方法:
- 全国范围内,基于人口的成年荷兰居民感染SARS-CoV-2的队列研究 (2020年6月 - 2022年3月).
- 将个人分为血液恶性瘤,固体恶性瘤或无恶性瘤组.
- 主要结局:严重的COVID-19 (住院治疗或死亡).
主要成果:
- 患有血液性恶性瘤的患者面临严重COVID-19的最高风险.
- 在这个群体中,COVID-19疫苗对严重疾病的有效性达到74%,根据变种,疫苗接种状态和接种以来的时间而有所不同.
- 最近诊断和某些治疗方法 (例如CD38/CD20抗体,蛋白酶体抑制剂) 的风险最高.
结论:
- 接种COVID-19疫苗显著降低了血液性恶性瘤患者的严重COVID-19风险,尽管风险仍然存在.
- 恶性瘤类型,诊断后的时间和特定的治疗方法是严重COVID-19的关键决定因素.
- 这些发现可以为免疫功能低下的癌症患者的呼吸道病毒感染提供增强的预防和治疗策略.
相关概念视频
Cancer Vaccines
960
Cancer treatment vaccines are a rapidly evolving field that offers a promising approach to immunotherapy. Unlike traditional vaccines that prevent diseases, cancer treatment vaccines are designed to treat existing cancers by stimulating the immune system to recognize and attack cancer cells.
Cancer vaccines come in two categories: preventive (prophylactic) and treatment (active). Preventive vaccines, such as the Human Papillomavirus (HPV) vaccine, protect against viruses that cause certain...
Cancer vaccines come in two categories: preventive (prophylactic) and treatment (active). Preventive vaccines, such as the Human Papillomavirus (HPV) vaccine, protect against viruses that cause certain...
960
Bone Marrow Sampling and Transplants
881
Bone marrow transplant is a potential cure for several diseases, including cancer and specific genetic disorders. Notably, this procedure is applicable for patients suffering from aplastic anemia, certain types of leukemia, severe combined immunodeficiency disease (SCID), Hodgkin's disease, non-Hodgkin's lymphoma, multiple myeloma, thalassemia, sickle-cell disease, and certain cancers.
The transplant begins with high doses of chemotherapy and radiation treatment, which aim to destroy...
The transplant begins with high doses of chemotherapy and radiation treatment, which aim to destroy...
881
Treatment Resistant Cancers
3.7K
Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
3.7K
Rous Sarcoma Virus (RSV) and Cancer
6.2K
Rous Sarcoma virus or RSV was discovered by F. Peyton Rous in the year 1911 as a filterable transmissible agent that could cause tumors in chickens. He won a Nobel Prize for this discovery in 1966. His experiments clearly demonstrated that some cancers could be caused by infectious agents and led to the discovery of many more cancer-causing viruses in animals as well as humans.
RSV is a retrovirus that contains two copies of a plus-strand RNA genome. Its genome consists of four main open...
RSV is a retrovirus that contains two copies of a plus-strand RNA genome. Its genome consists of four main open...
6.2K
Cancer Survival Analysis
645
Cancer survival analysis focuses on quantifying and interpreting the time from a key starting point, such as diagnosis or the initiation of treatment, to a specific endpoint, such as remission or death. This analysis provides critical insights into treatment effectiveness and factors that influence patient outcomes, helping to shape clinical decisions and guide prognostic evaluations. A cornerstone of oncology research, survival analysis tackles the challenges of skewed, non-normally...
645
Regulation of Hematopoietic Stem Cells
4.0K
All blood and immune cells are produced from the multipotent hematopoietic stem cells (HSCs) by the process of hematopoiesis. However, they all have a limited life span. In addition, many are depleted in immune surveillance or combatting an injury or infection. This makes blood one of the most regenerative tissues. Hematopoiesis helps replenish these blood and immune cells, restoring the body's normal functioning. However, overproduction of blood and immune cells can make them cancerous or...
4.0K


